BIOMARIN PHARMACEUTICAL INC (BMRN) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001048477 · SEC filings checked Oct 17, 2026

    Next report
    Nov 9, 2026
    Estimated from reporting history (94-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $54.68
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $0.39
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 140.2

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 6, 2026$989.7M$44.8M$0.23Filing
    Mar 31, 2026May 4, 2026$766.2M$105.5M$0.54Filing
    Dec 31, 2025Jan 12, 2026$874.6M$-46.6M$-0.22Filing
    Sep 30, 2025Oct 27, 2025$776.1M$-30.7M$-0.16Filing
    Jun 30, 2025Aug 4, 2025$825.4M$240.5M$1.23Filing
    Mar 31, 2025May 1, 2025$745.1M$185.7M$0.95Filing
    Dec 31, 2024Feb 19, 2025$747.3M$125.0M$0.65Filing
    Sep 30, 2024Oct 29, 2024$745.7M$106.1M$0.55Filing

    What would BIOMARIN PHARMACEUTICAL INC have to report for its valuation to change?

    At $54.68, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 64.3% a year, to $4.67. On that path the next quarter needs diluted EPS near $-0.26, against $-0.16 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year64.3%64.3%
    EPS needed in final year$4.67$4.67

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. BMRN goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.